THU0688 ASSESSMENT OF THE QRISK2, QRISK3, SLE CARDIOVASCULAR RISK EQUATION, FRAMINGHAM AND MODIFIED FRAMINGHAM RISK CALCULATORS AS PREDICTORS OF CARDIOVASCULAR DISEASE EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS

Background Systemic lupus erythematosus (SLE) is recognized as an independent risk factor for cardiovascular disease (CVD), and patients with SLE are at an elevated risk of CVD compared to the general population1. The complex interplay between conventional CVD risk factors, the inflammation caused by SLE and the pharmacological treatment of SLE contributes toward CVD risk1. Despite knowledge of this increased risk, there is no agreement on the use of risk assessment tools in the prediction of CVD in SLE. The Modified Framingham Risk Score (mFRS), QRISK3 and SLE Cardiovascular Risk Equation (SLECRE) have been introduced as promising CVD risk assessment tools considering SLE in prognosticating patients. Objectives To determine which cardiovascular risk assessment tool amongst the QRISK2, QRISK3, SLECRE, Framingham (FRS) and mFRS best predicts CVD events in SLE. Methods Single-centre analyses on prospectively collected data of 1887 SLE patients were performed to compute 10-year CVD risk scores for each tool. Tools’ scores were evaluated against CVD events at or within ten years for cases (CVD events) and controls (no CVD events). For cases, the index date for risk score calculation was chosen 10 years, or as close to 10 years as possible prior to the CVD event. For controls, risk scores were calculated as close to 10 years as possible prior to the most recent clinic appointment. Proportions of patients classified as low (<10%), median (10-20%) and high risk (>20%) of developing CVD according to each tool were determined. Sensitivity, specificity, positive/negative predictive values and c-statistics of these tools were analysed. Results 232 total CVD events were identified in the cohort including myocardial infarction, stroke, transient ischemic attack, heart failure and CVD death. QRISK2 and FRS risk-stratification was similar, while QRISK3 and mFRS risk-stratification was similar (Figure 1). The SLECRE classified the highest number of patients as median-high risk (Figure 1). The sensitivities and specificities are as follows for each tool: QRISK2 (19%, 93%), FRS (22%, 93%), mFRS (46%, 83%), QRISK3 (47%, 78%), SLECRE (61%, 63%). The tools were similar in negative predictive value, ranging from 89% (QRISK2) to 92% (SLECRE). The FRS and mFRS had the greatest c-statistics, both equalling 0.73, demonstrating the greatest predictive accuracy amongst the tools, while the QRISK3 had the lowest (0.67).Figure 1 Percentage of patients considered low (<10%), median (10-20%) and high risk (>20%) between cases (CVD, n=232) and controls (no-CVD, n=1655) according to the FRS, mFRS, QRISK2, QRISK3 and SLE CRE. Conclusion While the mFRS performance was superior to the FRS, the QRISK3 did not outperform the mFRS. Although the SLECRE had the highest sensitivity, it had the lowest specificity, demonstrated by grouping the most cases and controls in the median-high risk category. Several factors are important to consider when deciding which risk assessment tools to utilize: ease of use/computation, sensitivity/specificity, and laboratory data accessibility. Of the tools currently available, the mFRS is a practical tool with a simple, intuitive scoring system appropriate for the ambulatory clinic setting based on the initial weighting of the FRS while adjusting for SLE. However, much room for improvement exists in predicting CVD in SLE. References 1. Hippisley-Cox, J., Coupland, C., & Brindle, P. (2017). Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ, 357, j2099. Disclosure of Interests Jagan Sivakumaran: None declared, Paula Harvey: None declared, Jiandong Su: None declared, Ahmed Omar: None declared, Nicole Anderson: None declared, Dafna D Gladman Grant/research support from: AbbVie, Amgen, Celgene, Lilly, Novartis, Pfizer, and UCB, Consultant for: AbbVie, Amgen, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB, Murray B Urowitz Grant/research support from: GSK, Consultant for: BMS, Celgene, GSK, Lilly, UCB, Zahi Touma Grant/research support from: GSK Canada, Consultant for: UBC, Pfizer, Janssen, Inc